FXYD5 and cancer: To further explore the dysadherin/CA9 axis in CRC, we analyzed CA9 expression in cancer (GSE21510) and stratified 156 CRC patient samples into high- and low-CA9 expression groups on the basis of the median expression value (Fig. 5j).